2.18
3.11%
-0.07
After Hours:
2.28
0.10
+4.59%
Genetic Technologies Ltd. ADR stock is currently priced at $2.18, with a 24-hour trading volume of 31,893.
It has seen a -3.11% decreased in the last 24 hours and a -14.84% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.28 pivot point. If it approaches the $2.09 support level, significant changes may occur.
Previous Close:
$2.25
Open:
$2.31
24h Volume:
31,893
Market Cap:
$9.96M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.6093
EPS:
-0.604
Net Cash Flow:
-
1W Performance:
-10.66%
1M Performance:
-14.84%
6M Performance:
+211.87%
1Y Performance:
+105.66%
Genetic Technologies Ltd. ADR Stock (GENE) Company Profile
Name
Genetic Technologies Ltd. ADR
Sector
Industry
Phone
61 3 8412 7000
Address
60-66 Hanover Street, Fitzroy, VIC
Genetic Technologies Ltd. ADR Stock (GENE) Latest News
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
GlobeNewswire Inc.
Genetic Technologies Announces $2 Million Registered Direct Offering
GlobeNewswire Inc.
Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market
GlobeNewswire Inc.
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Benzinga
GTG to launch U.S. Customer Digital Media Sales Campaign
GlobeNewswire Inc.
Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire Inc.
Genetic Technologies Ltd. ADR Stock (GENE) Financials Data
There is no financial data for Genetic Technologies Ltd. ADR (GENE). Check out other stocks for more information.
About Genetic Technologies Ltd. ADR
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
Cap:
|
Volume (24h):